OptiBiotix Health PLC Director's dealing (3706U)
July 12 2018 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 3706U
OptiBiotix Health PLC
12 July 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Director's dealing
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care was notified on 11 July 2018 that Neil Davidson,
Non-Executive Chairman of the Company, acquired 210,000 ordinary
shares in the Company on 11 July 2018, representing 0.25% of the
Company's issued share capital, at a price of 71 pence per
share.
Previously to this notification, Mr Davidson held 165,000
ordinary shares in the Company. Therefore Neil Davidson's total
shareholding represents 0.44% of the Company's issued share
capital.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 and the person who arranged
for release of this announcement on behalf of the Company was
Stephen O'Hara, Chief Executive.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Cairn Financial Advisers LLP Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Abigail Wayne (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
-------------------------------------------------------------------------------
a. Name Neil Davidson
--------------------------------------- --------------------------------------
2 Reason for notification
--------------------------------------- --------------------------------------
a. Position/Status Non-Executive Chairman
--------------------------------------- --------------------------------------
b. Initial notification/ Initial Notification
Amendment
--------------------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------
a. Name OptiBiotix Health plc
--------------------------------------- --------------------------------------
b. LEI 213800UKYQFT941QHS14
--------------------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-------------------------------------------------------------------------------
a. Description of
the financial Ordinary shares
instrument, type
of instrument
Identification ISIN: GB00BP0RTP38
Code
--------------------------------------- --------------------------------------
b. Nature of the Purchase of ordinary shares
transaction
--------------------------------------- --------------------------------------
c. Price(s) and volume(s) Price(s) per Volume(s)
share
--------------------------------------- -------------------
71 pence 210,000
------------------------------------------------------------------ -------------
d. Aggregated information
- Aggregated Volume 210,000
- Price 71 pence
--------------------------------------- --------------------------------------
e. Date of the transaction 11 July 2018
--------------------------------------- --------------------------------------
f. Place of the transaction AIM
--------------------------------------- --------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHQFLFFVDFBBBD
(END) Dow Jones Newswires
July 12, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024
